| 查看: 1985 | 回复: 22 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
审稿意见回来后，如何处理不合理的返修意见？
|
|||
|
我之前投了运筹优化领域的一个期刊ejor，第一轮审稿意见回来后，有三个专家，我按照他们的意见做了相应的修改并提交了回去，现在结果又回来了，第二和三个审稿人的意见是可以接收了。但是第一个审稿人reviewer 1又提出了两个意见，这两个意见我认为是不能改的，我个人认为是reviewer 1没正确理解文章所做出的不合理意见。然后主编看到这种情况，就有了以下的决定。 主编： As you can see from the reports enclosed, the referees hold conflicting views on your paper. In these circumstances, it has been decided that your paper should be reconsidered for publication in the EUROPEAN JOURNAL OF OPERATIONAL RESEARCH if you will revise it to meet the enclosed referees' comments. (You may wish to argue that some comments are invalid). The most critical comments from Reviewer #1 made me doubt whether I should reconsider your paper, so I need convincing arguments from you and a thorough revision to counterbalance the critical comments. When resubmitting the revised paper, please provide your answers to the referees, separately for each referee. Please also ensure that you have cited recent and relevant publications in EJOR and other OR journals. I am most grateful for your interest and hope that you will not be deterred from resubmitting this paper in the very near future. You are advised to revise and resubmit your manuscript by the Mar 09, 2026. After this time the review process of this submission will be terminated, by withdrawing your paper from the Editorial Manager, and the revised paper will have to be submitted as a new submission. Reviewer #2: All my comments have been suitably addressed. I recommend that this paper be accepted in its present version. I congratulate the authors on a very interesting paper with a solid contribution. Reviewer #3: Thank you for your careful and meticulous revision. In this revision, I find that the manuscript has fully responded to the reviewer comments from the first round. The writing and flow has been substantially improved, and the motivations, contributions, literature review, and conclusions were carefully revised. The parameter settings for the case studies have also been sufficiently justified, and I appreciate the additional figures and plots to help the audience understand the results. The quality of the article has been substantially improved after addressing all the comments from the reviewers. I have no remaining requests for revision, and I appreciate your thorough and professional response. Good luck with your future research. Reviewer #1: Thanks for the efforts that the authors have put into revising the manuscript. However, I feel that my earlier concerns have not been fully addressed. And in my view, the current version has not yet reached the standard required for publication in EJOR. Below, I outline the major points that still need attention. 意见1：。。。。。。 意见2：。。。。。。意见1和2我就不详细列出来了，因为涉及具体的文章内容。 Overall, I like the method proposed by the authors and I can see the value, however, I find that both the depth of analysis and the clarity of presentation still require substantial improvement. 现在我的可选行动方案是： (1) 我不会再修改了，但是给主编发个邮件，解释Reviewer #1的两个个人认为不合理的意见，然后改投另一个期刊。 (2) 我不可能再大修了，但会做一些句子连贯上的小修，然后在Response letter写出个人认为的修改意见的不合理之处，然后再重新提交ejor，我估计会不被接受，所以这时候是不是系统上只有这一次新的submission的拒绝记录(如果不被接受)？因为之前的submission和Reviewer2和3的意见都被删除了？ 如果我采取方案2，然后被拒绝后再去投其它omaga一类的期刊会不会有什么影响？ 谢谢~ |
回复此楼» 猜你喜欢
面上函评意见出来了，像什么等级？
已经有17人回复
-
为什么国自然不能直接公布
已经有5人回复
-
梦想
已经有7人回复
-
学科评审组评审是指会评吗？
已经有4人回复
-
面上合作单位盖章
已经有8人回复
-
为什么资助数各大高校都创新高，自己申请怎么就这么难
已经有14人回复
-
小白求助 投论文要求的highlights应该如何写
已经有4人回复
-
麻烦专家们看看评委们的意见（F口面上）
已经有12人回复
-
怎么看青基中了没有啊
已经有6人回复
-
国社科又开始会评了，不知道这次命运如何
已经有11人回复
» 抢金币啦！回帖就可以得到:
-
【征稿中！】2026年机械、制造技术与材料国际会议 (MEMTM 2026)
+1/873
-
【IEEE列表会议征稿 】2026年第六届控制理论与应用国际会议（ICoCTA 2026）
+5/840
-
云南大学丁军桥团队2027年博士招生
+1/811
-
昆明理工大学智能车辆技术团队招聘博士后
+3/207
-
天平合规性问题
+1/91
-
【半导体薄膜代工】ALD/CVD/磁控溅射/热蒸发全工艺
+1/88
-
南方科技大学刘科院士团队诚聘矿物浮选分离方向研究助理
+1/83
-
大湾区大学刘天辉课题组招收2027级博士生（与中山大学物理学院联合培养）
+1/37
-
大湾区大学刘天辉课题组招收2027级博士生（与中山大学物理学院联合培养）
+1/36
-
山东大学-山东字节信息智能技术实验室2026年招聘博士后
+2/20
-
评职称需要，卖发明专利了:D有技术储备需求的设备厂商可联系
+1/19
-
浙江大学物理高等研究院袁怀洋课题组诚聘博士和博士后
+1/14
-
中国药科大学陈达威课题组招收2027年博士研究生 （药理学）
+1/6
-
【科研诚信】武汉轻工大学何江玲3篇论文：涉嫌抄袭、成组数据重复、制造虚假显著
+1/5
-
义翘神州推出全长p-Tau217蛋白，助力阿尔茨海默病下一代生物标志物检测开发
+1/5
-
结肠炎多维度分子解析：炎症‑免疫‑肠道屏障一体化检测策略
+1/4
-
项目助理招聘启事
+1/2
-
南方科技大学环境科学与工程学院陈洪副教授课题组2026年科研助理招聘启事
+1/1
-
义翘神州TR-FRET激酶检测试剂盒助力高通量药物筛选
+1/1
-
义翘神州TR-FRET激酶检测试剂盒助力高通量药物筛选
+1/1
9楼2025-09-13 19:47:59
3楼2025-09-13 18:21:30
简单回复
tzynew2楼
2025-09-13 18:16
回复
BayesInter(金币+1): 谢谢参与
o 发自小木虫手机客户端
2025-09-13 18:25
回复
zusn6楼
2025-09-13 18:48
回复
我才是肖牧冲7楼
2025-09-13 19:18
回复
BayesInter(金币+1): 谢谢参与
。 发自小木虫手机客户端
elainzaizai10楼
2025-09-13 19:54
回复
没有感觉的鱼12楼
2025-09-13 20:57
回复
BayesInter(金币+1): 谢谢参与
。 发自小木虫IOS客户端
明天会更好12313楼
2025-09-13 21:05
回复
BayesInter(金币+1): 谢谢参与
。 发自小木虫手机客户端
ygxzxd14楼
2025-09-13 21:27
回复
BayesInter(金币+1): 谢谢参与
?? 发自小木虫IOS客户端
投票:
